| Evaluation of drug dosing in renal failure MA Hammad, AA Khamis, KM Al-Akhali, TM T Elsayed, AM Alasmri, ... IOSR Journal of Pharmacy and Biological Sciences 11 (5), 39-50, 2016 | 11 | 2016 |
| A prospective study of prevalence of uncontrolled glycaemia in type 2 diabetes mellitus outpatients.: 60. M Hammad, DM Noor, SS Sulaiman, N Aziz, Y Elsobky Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy (ACCP …, 2016 | 8 | 2016 |
| Building capacity in evidence-based medicine in low-income and middle-income countries: problems and potential solutions PJ Gill, SM Ali, Y Elsobky, RC Okechukwu, TB Ribeiro, ... BMJ evidence-based medicine 26 (3), 82-84, 2021 | 7 | 2021 |
| The AMR Challenge CDC Centers for Disease Control and Prevention https://www.cdc.gov/drugresistance/intl-activities/amr-challenge.html#n, N …, 2019 | 7 | 2019 |
| Quality evaluation and survey of the essential need for drug information centers MM Wen, H Aref, A Abozaid, NH Kandil, YH Elsobky Int J Pharm Pharm Sci 8 (11), 137-143, 2016 | 5 | 2016 |
| Building capacity in evidence-based medicine in low-income and middle-income countries: problems and potential solutions. BMJ Evid Based Med. 2019 PJ Gill, SM Ali, Y Elsobky, RC Okechukwu, TB Ribeiro, ... | 5 | |
| 685. Evaluation of myalgia related adverse event reports attributed to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors within the FDA adverse events reporting … Y Elsobky, M Mohamed The 35th International Conference on Pharmacoepidemiology & Therapeutic Risk …, 2019 | 2* | 2019 |
| A Cross-Sectional Study on Board Certified Pharmacists in Arab Countries 2018 Update MA Hammad, KM Al Akhali, Y Elsobky International Journal of Humanities and Social Sciences 14 (1), 35-44, 2014 | 1 | 2014 |
| Gabapentinoid abuse, suicide and behavior related adverse event reports: Data mining within FDA adverse events reporting system (FAERS) Y Elsobky Journal of Pharmacological and Toxicological Methods 105, 106701, 2020 | | 2020 |
| Medication trade names; are they intended to “Trick” or can they help to “Treat”? Y Elsobky, I Mohamed https://ebmlive.org/medication-trade-names-are-they-intended-to-trick-or-can …, 2019 | | 2019 |
| 54. The story behind drug trade names; a deeper insight into the pharmaceutical market Y Elsobky BMJ Evidence-Based Medicine 24 (Suppl 1), A32-A33, 2019 | | 2019 |
| Egyptian Knowledge bank "Trainer champion" Award YH Elsobky https://m.facebook.com/story.php?story_fbid=1030097110670581&id=386064755073823, 2019 | | 2019 |
| Evaluation of spontaneous adverse event reports for congenital and neonatal birth problems attributed to ondansetron within the FDA adverse events reporting system (FAERS) MA Mekkawy, OF Khedr, H Shokr, YH Elsobky PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 27 (S2), 230-230, 2018 | | 2018 |
| The evaluation of the BPS certification process; a focus on its impact in Egypt Y Elsobky, D Atta, A Dersawy 2015 ACCP Global Conference on Clinical PharmacyAt: San Francisco …, 2015 | | 2015 |
| Author Archives: CEBM BC Globally, EBML Blog | | |
| Medication trade names; are they intended to “Trick” or can they help to “Treat”? BC Globally, EBML Blog | | |
Ming Ming WenDept. of Pharmaceutics & Pharmaceutical Technology, Faculty of Pharmacyبريد إلكتروني تم التحقق منه على pua.edu.eg
